The proliferation of cardiac‐related biomarkers and advocacy for their use has often come
without adequate discussion of limitations in the interpretation of values and their best use in …

Opinion statement Investigation of the complex biochemical pathways that underlie heart
failure (HF) has led to the recognition of multiple molecular markers that may help to …

Heart failure (HF) may be considered as the fatal finishing line of all cardiovascular
disorders. Despite advances in the understanding and treatment, it still has a poor …

Biological markers have served for diagnosis, risk stratification and guided therapy of heart
failure (HF). Our knowledge regarding abilities of biomarkers to relate to several pathways of …

Despite the enhanced knowledge of the pathophysiology of heart failure (HF), it still remains
a serious syndrome with substantial morbidity, mortality, and frequent hospitalizations …

The approval of new heart failure (HF) therapies has slowed over the past two decades in
part due to the high costs of conducting large randomized clinical trials that are needed to …

Abstract Purpose of Review Cardiac biomarkers play important roles in routine evaluation of
cardiac patients. But while these biomarkers can be extremely valuable, none of them …

The pathophysiology of heart failure is complex, and the list of biomarkers representing
distinct pathophysiologic pathways is growing rapidly. Other articles in this issue of the Heart …

An always-rising prevalence of heart failure (HF), formerly classified as an emerging
epidemic in 1997 and still representing a serious problem of public health, imposes on us to …

The increasing use of cardiac biomarkers in the diagnosis and management of heart failure
(HF) has led to their inclusion in clinical practice guidelines. Studies have demonstrated that …